CTOs on the Move

Catalyst Pharmaceuticals

www.catalystpharma.com

 
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette`s Disorder.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Perlan Therapeutics Inc

Perlan Therapeutics Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AN2 Therapeutics

AN2 Therapeutics is a biopharmaceutical company that develops therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.

hope pharma inc

hope pharma inc is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

JASPER CLINICAL RandD INC

JASPER CLINICAL R&D INC is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.